leuprolide mesylate · Accord · NDA 219745
Camcevi Etm
Earliest generic entry, as listed
1 Jan 2039
Blocked by patent: US 11717555.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11717555 | drug product · sets the listed date | 1 Jan 2039 |
| US 12133878 | drug product | 18 Dec 2037 |
| US 9572857 | drug product | 2 Aug 2029 |
| US 10646572 | drug product | 16 Jan 2027 |
| US 9744207 | drug product | 16 Jan 2027 |
Exclusivities · 1 unexpired
| NS | new strength | 25 Aug 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219745 · 001 · RLD | emulsion, subcutaneous | EQ 21MG BASE | 1 Jan 2039 |